Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma.

Publication ,  Journal Article
Ajani, JA; Abbruzzese, JL; Markowitz, AB; Patt, YZ; Daugherty, K
Published in: Invest New Drugs
February 1993

Based on encouraging in vitro and in vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1-5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1-5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.

Duke Scholars

Published In

Invest New Drugs

DOI

ISSN

0167-6997

Publication Date

February 1993

Volume

11

Issue

1

Start / End Page

67 / 69

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Middle Aged
  • Male
  • Interferon-alpha
  • Humans
  • Female
  • Etoposide
  • Drug Synergism
  • Colorectal Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ajani, J. A., Abbruzzese, J. L., Markowitz, A. B., Patt, Y. Z., & Daugherty, K. (1993). Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs, 11(1), 67–69. https://doi.org/10.1007/BF00873914
Ajani, J. A., J. L. Abbruzzese, A. B. Markowitz, Y. Z. Patt, and K. Daugherty. “Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma.Invest New Drugs 11, no. 1 (February 1993): 67–69. https://doi.org/10.1007/BF00873914.
Ajani JA, Abbruzzese JL, Markowitz AB, Patt YZ, Daugherty K. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs. 1993 Feb;11(1):67–9.
Ajani, J. A., et al. “Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma.Invest New Drugs, vol. 11, no. 1, Feb. 1993, pp. 67–69. Pubmed, doi:10.1007/BF00873914.
Ajani JA, Abbruzzese JL, Markowitz AB, Patt YZ, Daugherty K. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs. 1993 Feb;11(1):67–69.
Journal cover image

Published In

Invest New Drugs

DOI

ISSN

0167-6997

Publication Date

February 1993

Volume

11

Issue

1

Start / End Page

67 / 69

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Middle Aged
  • Male
  • Interferon-alpha
  • Humans
  • Female
  • Etoposide
  • Drug Synergism
  • Colorectal Neoplasms